Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

YUE DA INTERNATIONAL HOLDINGS LIMITED
悅達國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 629)

APPOINTMENT OF EXECUTIVE DIRECTOR

The Board is pleased to announce that Mr. Chen Zhongjian was appointed as an executive Director of the Company with effect from 13 November 2026.

The board (the "**Board**") of directors (the "**Director(s)**") of Yue Da International Holdings Limited (the "**Company**", together with its subsidiaries, the "**Group**") hereby announces that Mr. Chen Zhongjian ("**Mr. Chen**") was appointed as an executive Director with effect from 13 November 2026.

Set out below are the biographical details of Mr. Chen.

Mr. Chen, aged 36, holds a bachelor's degree and a master's degree in Pharmacy from Shanghai Jiao Tong University School of Medicine, and is a licensed pharmacist in the People's Republic of China ("**PRC**"). Mr. Chen is currently the deputy general manager of the Company. Before joining the Group, Mr. Chen worked in Shanghai Jiao Tong University School of Medicine Ruijin Hospital (上海交通大學醫學院附屬瑞金醫院) ("**Ruijin Hospital**") as a pharmacist from July 2012 to June 2015. Following his departure from Ruijin Hospital, Mr. Chen pursued full-time postgraduate studies at Shanghai Jiao Tong University School of Medicine from September 2015 to June 2018, where he obtained a master's degree in Pharmacy. Mr. Chen subsequently served as an investment manager at Shanghai Yuanda Industrial and Financial Investment Management Co., Ltd. (上海遠大產融投資管理有限公司) and a senior investment manager at Ningbo Yanchuang Yongming Private Equity Fund Management Co., Ltd. (寧波燕創甬明私募基金管理有限公司) from July 2018 to July 2020. From August 2020 to December 2025, Mr. Chen served as a senior manager of the strategic development department of Sinopharm Group Co. Ltd. (stock code: 1099), a company listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**"). Mr. Chen has over 10 years of study and work experience in the healthcare and healthcare investment fields.

The Company entered into a letter of appointment with Mr. Chen for a term of three years commencing on 13 November 2026, which will be automatically renewed unless otherwise agreed by the Company and Mr. Chen in writing or until his appointment is terminated in accordance with the provisions thereto. Mr. Chen will hold office as the executive Director until the Company's first general meeting after his appointment and will be subject to re-election at such meeting pursuant to the articles of association of the Company (the "**Articles**"). Thereafter, Mr. Chen's directorship is subject to the provisions of retirement by rotation and re-election of Directors under the Articles. Mr. Chen will not receive any remuneration in respect of his appointment as an executive Director other

than the remuneration payable to him under his service contract as deputy general manager of the Company.

The Company separately entered into a service contract with Mr. Chen on 15 December 2025 on his appointment as the deputy general manager of the Company for a term of one year commencing on 15 December 2025 which will be renewed if it is agreed by the Company and Mr. Chen. Mr. Chen is entitled to a basic salary of RMB300,000 per annum and a performance-related pay of RMB450,000 per annum under his service contract, which was determined with reference to Mr. Chen's roles and responsibilities and the prevailing market conditions. Pursuant to the relevant laws and regulations in the PRC, the Group also makes contributions to the state-managed retirement schemes in the PRC on behalf of Mr. Chen.

Save as disclosed above, as at the date of this announcement, Mr. Chen confirms that he (i) does not have any relationship with any Director, senior management, chief executive, substantial or controlling shareholder of the Company and holds no other positions within the Company and other members of the Group; (ii) does not have nor is deemed to have any interest in the shares or underlying shares of the Company or its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); and (iii) does not hold any other directorships in any other public companies, the securities of which are listed on any securities market in Hong Kong or overseas, in the last three years up to the date of this announcement.

Save as disclosed above, there are no other matters or information that need to be brought to the attention of the shareholders of the Company or to be disclosed pursuant to Rules 13.51(2) of the Rules Governing the Listing of Securities on the Stock Exchange in relation to the aforesaid appointment.

The Board would like to express its warm welcome to Mr. Chen to the Board.

By order of the Board
Yue Da International Holdings Limited
Ji Hulin
Chairman and Executive Director

Hong Kong, 13 November 2026

As at the date of this announcement, the Board comprises the following members: (a) as executive Directors, Mr. Ji Hulin, Mr. Xue Zhicheng, Mr. Pan Mingfeng, Dr. Teng Songsong and Mr. Chen Zhongjian; (b) as non-executive Director, Mr. Yan Bingde; and (c) as independent non-executive Directors, Dr. Liu Yongping, Ms. Tang Lo Nar and Dr. Wang Li.

If there is any inconsistency in this announcement between the Chinese and English versions, the English version shall prevail.